Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sulindac

FDA-approved product (tablet, oral), marketed as Clinoril, Sulindac.

Registered studies
40
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Sulindac
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Osteoarthritis
  • Rheumatic disease
  • Rheumatoid arthritis
  • Spondylitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Acetic acid derivatives and related substances
FDA pharmacologic class
Nonsteroidal Anti-inflammatory Drug FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA29.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

40registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sulindac in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sulindac with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer

    NCT00041314 · start 2002-10-04

    Registered record
    Registry ID
    NCT00041314
    Conditions
    Lung Cancer
    Interventions
    carboplatin; exisulind; gemcitabine hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-10-04
    Completion
    2007-06-15
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    Interventioncarboplatin; exisulind; gemcitabine hydrochloride
    PhasePhase 2
    Registry statusCompleted

  • Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer

    NCT00041054 · start 2002-06

    Registered record
    Registry ID
    NCT00041054
    Conditions
    Lung Cancer
    Interventions
    carboplatin; etoposide; exisulind
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-06
    Completion
    2008-02
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    Interventioncarboplatin; etoposide; exisulind
    PhasePhase 2
    Registry statusCompleted

  • Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

    NCT00283803 · start 2002-03-12

    Registered record
    Registry ID
    NCT00283803
    Conditions
    Prostate Cancer
    Interventions
    Exisulind; luteinizing hormone-releasing hormone (LHRH) agonist; Antiandrogen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-03-12
    Completion
    2011-10
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionExisulind; luteinizing hormone-releasing hormone (LHRH) agonist; Antiandrogen
    PhasePhase 2
    Registry statusCompleted

  • Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer

    NCT00039520 · start 2002-01

    Registered record
    Registry ID
    NCT00039520
    Conditions
    Breast Cancer
    Interventions
    docetaxel; sulindac
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-01
    Completion
    2008-07
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventiondocetaxel; sulindac
    PhasePhase 2
    Registry statusCompleted

  • Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients

    NCT00072618 · start 2001-10

    Registered record
    Registry ID
    NCT00072618
    Conditions
    NSCLC
    Interventions
    Exisulind
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2001-10
    Completion
    2003-08
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC
    InterventionExisulind
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients

    NCT00085826 · start 2001-04

    Registered record
    Registry ID
    NCT00085826
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Exisulind
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-04
    Completion
    2004-12
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionExisulind
    PhasePhase 3
    Registry statusCompleted

  • Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients

    NCT00037609 · start 2001-01

    Registered record
    Registry ID
    NCT00037609
    Conditions
    Breast Neoplasms; Metastases, Neoplasm
    Interventions
    Capecitabine; Exisulind
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2001-01
    Completion
    2003-02
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms; Metastases, Neoplasm
    InterventionCapecitabine; Exisulind
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis

    NCT00026468 · start 1999-07

    Registered record
    Registry ID
    NCT00026468
    Conditions
    Colorectal Cancer; Small Intestine Cancer
    Interventions
    exisulind
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Withdrawn
    Start
    1999-07
    Completion
    1999-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer; Small Intestine Cancer
    Interventionexisulind
    PhasePhase 2 / Phase 3
    Registry statusWithdrawn

  • Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps

    NCT00118365 · start 1998-07

    Registered record
    Registry ID
    NCT00118365
    Conditions
    Precancerous Condition
    Interventions
    placebo; eflornithine; sulindac; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1998-07
    Completion
    2008-08
    Enrolment
    375

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrecancerous Condition
    Interventionplacebo; eflornithine; sulindac; laboratory biomarker analysis
    PhasePhase 3
    Registry statusCompleted

  • Sulindac and Plant Compounds in Preventing Colon Cancer

    NCT00003365 · start 1996-08

    Registered record
    Registry ID
    NCT00003365
    Conditions
    Colorectal Cancer
    Interventions
    curcumin; rutin; quercetin; sulindac
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    1996-08
    Completion
    2006-07
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    Interventioncurcumin; rutin; quercetin; sulindac
    PhaseNot applicable
    Registry statusTerminated